InsiderTrades

Form 4 for DYN Dyne Therapeutics, Inc.

Accepted 2024-05-22 00:00:00 ET · period of report 2024-05-20 · accession 0000950170-24-063737 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2024-05-22 2024-05-20 DYN Beskrovnaya Oxana CSO S - Sale+OE $32.96 -30.4K 149.6K -17% -$1.00M
DT 2024-05-22 2024-05-20 DYN Beskrovnaya Oxana CSO M - OptEx $1.03 +30.4K 180.1K +20% +$31.3K
DT 2024-05-22 2024-05-20 DYN Beskrovnaya Oxana CSO M - OptEx $0.00 -30.4K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-20 S D 17,134 $32.49 162,939 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.00 to $33.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
2 Common Common Stock 2024-05-20 S D 12,147 $33.51 150,792 D — — (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $33.01 to $34.01, inclusive.
3 Common Common Stock 2024-05-20 S D 1,145 $34.08 149,647 D — — (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.02 to $34.16, inclusive. (F5) Includes 130,308 unvested RSUs.
4 Common Common Stock 2024-05-20 M A 30,426 $1.03 180,073 D — —
5 Derivative Stock option (right to buy) 2024-05-20 M D 30,426 $0.00 0 D $1.03 · — to 2030-01-05 30,426 Common Stock (F6) The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter.